Yubo Shi

Mr. Yubo Shi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2024 in Life
Verified
Journal Article
Open access
PDF file
YSYubo Shi
Yubo Shi
SFSufang Fang
Sufang Fang
XGXiaolong Gu
Xiaolong Gu
CHChengyu Hao
Chengyu Hao
FDFangchen Du
Fangchen Du
Xinming TangXinming Tang
Xinming Tang
Rabbit coccidiosis is caused by infection with one or, more commonly, several Eimeria species that parasitize the hepatobiliary ducts or intestinal epithelium of rabbits. Currently, there are eleven internationally recognized species of rabbit coccidia, with the complete mitochondrial (mt) genomes of six species commonly infecting rabbits having been sequenced and annotated. Eimeria kongi was initially discovered in 2011 and prompted a preliminary study on this species. Through traditional morphological analysis, E. kongi was identified as a novel species of rabbit coccidia. To further validate this classification, we sequenced and annotated its mitochondrial genome. The complete mt genome of E. kongi spans 6258 bp and comprises three cytochrome genes (cytb, cox1, cox3), fourteen gene fragments for the large subunit (LSU) rRNA, and nine gene fragments for the small subunit (SSU) rRNA, lacking transfer RNA (tRNA) genes. Moreover, phylogenetic analysis of the mitochondrial genome sequence of E. kongi revealed its clustering with six other species of rabbit coccidia into a monophyletic group. Additionally, E. irresidua and E. flavescens were grouped within the lineage lacking oocyst residuum, consistent with their morphological characteristics. Consistent with multiple molecular phylogenies, in this investigation, E. kongi was further confirmed as a new species of rabbit coccidia. Our research findings are of great significance for the classification of coccidia and for coccidiosis prevention and control in rabbits.

5 December 2024 in Animals
Verified
Journal Article
Open access
PDF file
SFSufang Fang
Sufang Fang
LMLinghai Meng
Linghai Meng
YSYubo Shi
Yubo Shi
CHChengyu Hao
Chengyu Hao
XGXiaolong Gu
Xiaolong Gu
Xinming TangXinming Tang
Xinming Tang
Coccidiosis is one of the most significant diseases affecting the rabbit industry and is caused by Eimeria. In a previous study, we identified a new species of Eimeria kongi (E. kongi-ZJK) from the northern region of China (Zhangjiakou, Hebei Province) and studied its pathogenicity and immunogenicity. The aim of this study was to evaluate the pathogenicity, immunogenicity, and cross-immunogenicity from different geographical isolates of E. kongi for vaccine development. Two geographical isolates of E. kongi-QD from Qingdao, Shandong Province (eastern China), and E. kongi-CD from Chengdu, Sichuan Province (southwestern China), were isolated and identified. The pathogenicity, immunogenicity, and cross-immunogenicity among the three geographical isolates were evaluated. The pathogenicity results showed that after infecting rabbits with doses of 1 × 103 or fewer sporulated oocysts of E. kongi-QD and E. kongi-CD, the rabbits exhibited clinical symptoms but recovered quickly, indicating lower pathogenicity. Immunogenicity studies revealed that after immunizing rabbits with 1 × 103 sporulated oocysts of E. kongi-QD and E. kongi-CD for 14 days, followed by challenge with 1 × 104 homologous sporulated oocysts, the oocyst reduction rates in the immunized groups were 99.39% and 99.12%, respectively, compared with the non-immunized groups, demonstrating good immunogenicity. In cross-immunogenicity studies, rabbits were immunized with 1 × 103 sporulated oocysts of E. kongi-ZJK, E. kongi-QD, or E. kongi-CD and then challenged with 1 × 104 sporulated oocysts of heterologous isolate. The immunized groups showed no significant clinical symptoms, and the oocyst reduction rates ranged from 55.9% to 98.4%. E. kongi-CD exhibited cross-protection against E. kongi-ZJK and E. kongi-QD, making it an ideal candidate formulation for vaccine development.